Vor bio announces exploration of strategic alternatives to maximize shareholder value

Cambridge, mass., may 08, 2025 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the board of directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.
VOR Ratings Summary
VOR Quant Ranking